Galderma Wins FDA Clearance for Restylane Contour in Temple Hollowing — Narrower Indication, Broader Competitive Pressure

Yes. Galderma received FDA approval for Restylane Contour specifically for correction of temple hollowing, a narrowly defined indication that gives practices label authority to treat temple volume loss. This approval marks the first named indication for this anatomical zone, though practitioners have historically treated temples off-label with standard volumizers.

Each Restylane product targets different anatomical zones and has distinct rheology. Contour is now indicated for temple hollowing, Lyft is designed for deeper volumization, and Volbella targets lips and perioral lines. The differences in gel structure and particle size mean practices need to stock multiple SKUs and train staff on the clinical rationale for each.

Label approval provides marketing authority, payer recognition, and competitive positioning—not necessarily new clinical capability. For Galderma, the temple hollowing indication lets them claim a named zone and differentiate Restylane Contour in marketing, while practices gain the ability to bill and communicate the treatment as an approved use rather than off-label.

Yes. Allergan's Skinvive approval in the same window signals an industry-wide arms race in indication expansion. Manufacturers are systematically building out anatomically specific claims to own particular facial zones and gain competitive advantages in marketing and payer negotiations.

It reinforces the need to stock multiple filler products with different indications and rheologies. Practices must now educate staff on when to recommend Restylane Contour for temples versus Lyft or Volbella for other zones, increasing complexity in product selection and staff training.